Scinai Immunotherapeutics Ltd. Sponsored Adr (SCNI) has released an update.
Scinai Immunotherapeutics Ltd. is gaining traction with the development of its nanosized antibodies (NanoAbs), which promise significant clinical and commercial advantages over traditional human monoclonal antibodies. The company has highlighted the potential for NanoAbs in the treatment and prevention of diseases like psoriasis and COVID-19, with plans for a psoriasis clinical trial in the first half of 2025. Scinai’s pipeline also targets other large markets with underserved needs, aiming to leverage its platform for rapid response to emerging pandemic pathogens.
For further insights into SCNI stock, check out TipRanks’ Stock Analysis page.
